HRP20230433T1 - Antitumorski spojevi - Google Patents
Antitumorski spojevi Download PDFInfo
- Publication number
- HRP20230433T1 HRP20230433T1 HRP20230433TT HRP20230433T HRP20230433T1 HR P20230433 T1 HRP20230433 T1 HR P20230433T1 HR P20230433T T HRP20230433T T HR P20230433TT HR P20230433 T HRP20230433 T HR P20230433T HR P20230433 T1 HRP20230433 T1 HR P20230433T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- cancer
- compound according
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 29
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 6
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Claims (24)
1. Spoj sa formulom IE, ili njegova farmaceutski prihvatljiva sol ili ester:
[image]
pri čemu:
X je -NH- ili -O-;
R1 je -OH ili -CN;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je odabrano od -CH2NH2 i -CH2NHProtNH;
Ra je odabrano od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila;
Rb je odabrano od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
ProtNH je zaštitna grupa za amino.
2. Spoj prema patentnom zahtjevu 1 odabran od formula IEa ili IEb, ili njegova farmaceutski prihvatljiva sol ili ester:
[image]
pri čemu:
X je -NH- ili -O-;
R1 je -OH ili -CN;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je odabrano od -CH2NH2, i -CH2NHProtNH;
Ra je odabrano od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila;
Rb je odabrano od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
ProtNH je zaštitna grupa za amino.
3. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 pri čemu X je -NH-.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 pri čemu X je -O-.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu R4 je -CH2NH2.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5,pri čemu R1 je -OH.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu R2 je -C(=O)Ra grupa pri čemu Ra je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Ra odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila.
8. Spoj prema patentnom zahtjevu 7 pri čemu R2 je acetil.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8,pri čemu R3 je vodik ili -ORb pri čemu Rb je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Rb odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila.
10. Spoj prema patentnom zahtjevu 9 pri čemu R3 je vodik.
11. Spoj prema patentnom zahtjevu 9 pri čemu R3 je -ORb pri čemu Rb je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Rb odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila.
12. Spoj prema patentnom zahtjevu 11 pri čemu R3 je metoksi.
13. Spoj prema patentnom zahtjevu 1 sa formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester.
14. Spoj prema patentnom zahtjevu 1 sa formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester.
15. Spoj prema patentnom zahtjevu 1 sa formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester.
16. Spoj prema patentnom zahtjevu 1 sa formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester.
17. Spoj prema bilo kojem od patentnih zahtjeva 1 do 16, pri čemu je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartrat, malat, mandelat, metan sulfonat, p-toluensulfonat, natrij, kalij, kalcij, amonij, etilendiamin, etanolamin, N,N-dialkilenetanolamin, trietanolamin i baznih aminokiselina.
18. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 17 ili njegovu farmaceutski prihvatljivu sol ili ester i farmaceutski prihvatljiv nosač.
19. Dozni oblik koji sadrži farmaceutsku kompoziciju prema patentnom zahtjevu 18.
20. Spoj prema bilo kojem od patentnih zahtjeva 1 do 17, ili njegova farmaceutski prihvatljiva sol ili ester, ili kompozicija prema patentnom zahtjevu 18, ili dozni oblik prema patentnom zahtjevu 19, za primjenu kao lijek.
21. Spoj prema bilo kojem od patentnih zahtjeva 1 do 17, ili njegova farmaceutski prihvatljiva sol ili ester, ili kompozicija prema patentnom zahtjevu 18, ili dozni oblik prema patentnom zahtjevu 19, za primjenu u liječenju raka.
22. Spoj, kompozicija ili dozni oblik za primjenu prema patentnom zahtjevu 21, pri čemu je rak odabran od raka pluća uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika, raka prostate i raka želuca; pri čemu je poželjno rak odabran od raka pluća uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka dojke, raka gušterače i kolorektalnog raka.
23. Proces dobivanja spoja kako je definirano u bilo kojem od patentnih zahtjeva 1 do 17 ili njegove farmaceutski prihvatljive soli ili estera:
koji obuhvaća korak reagiranja spoja sa formulom II sa spojem formule III da se dobije spoj formule IV:
[image]
pri čemu (gdje je dozvoljeno mogućim supstituentnim grupama):
X je -NH- ili -O-;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je -CH2NHProtNH;
Ra je odabrano od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila;
Rb je odabrano od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
ProtNH je zaštitna grupa za amino;
i koji po izboru obuhvaća dodatni korak zamjene cijano grupe u spoju sa formulom IV sa hidroksi grupom da se dobije spoj formule IE, pri čemu R1 je OH.
24. Komplet koji sadrži terapijski efikasnu količinu spoja prema bilo kojem patentom zahtjevu 1 do 17 ili njegove farmaceutski prihvatljive soli ili estera i farmaceutski prihvatljiv nosač; komplet koji po izboru dalje sadrži uputstva za primjenu spoja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka debelog crijeva, raka dojke, raka gušterače, sarkoma, raka jajnika, raka prostate, kolorektalnog raka i raka želuca.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382228 | 2017-04-27 | ||
EP17382497 | 2017-07-26 | ||
EP22166571.4A EP4047002B1 (en) | 2017-04-27 | 2018-04-27 | Antitumoral compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230433T1 true HRP20230433T1 (hr) | 2023-07-07 |
Family
ID=62063080
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231233TT HRP20231233T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
HRP20230455TT HRP20230455T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
HRP20230433TT HRP20230433T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
HRP20191443 HRP20191443T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
HRP20191442 HRP20191442T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231233TT HRP20231233T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
HRP20230455TT HRP20230455T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191443 HRP20191443T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
HRP20191442 HRP20191442T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
Country Status (37)
Country | Link |
---|---|
US (5) | US10538535B2 (hr) |
EP (5) | EP3395821B1 (hr) |
JP (5) | JP6501947B2 (hr) |
KR (3) | KR102491180B1 (hr) |
CN (4) | CN114736219B (hr) |
AU (4) | AU2018260314C1 (hr) |
BR (1) | BR112019022282A2 (hr) |
CA (1) | CA3061518A1 (hr) |
CL (1) | CL2019003057A1 (hr) |
CO (1) | CO2019011967A2 (hr) |
CY (3) | CY1121884T1 (hr) |
DK (5) | DK3615544T3 (hr) |
EC (1) | ECSP19083967A (hr) |
ES (5) | ES2960063T3 (hr) |
FI (3) | FI4101855T3 (hr) |
HK (2) | HK1255938B (hr) |
HR (5) | HRP20231233T1 (hr) |
HU (5) | HUE046109T2 (hr) |
IL (3) | IL295044B2 (hr) |
JO (1) | JOP20190254A1 (hr) |
LT (5) | LT4047002T (hr) |
MA (2) | MA44020B1 (hr) |
MD (5) | MD4101855T2 (hr) |
ME (2) | ME03466B (hr) |
MX (3) | MX2021016054A (hr) |
MY (1) | MY198004A (hr) |
PH (1) | PH12019550224A1 (hr) |
PL (5) | PL4101855T3 (hr) |
PT (2) | PT3395821T (hr) |
RS (5) | RS64200B1 (hr) |
SG (2) | SG10201913300YA (hr) |
SI (5) | SI4101855T1 (hr) |
TN (2) | TN2019000210A1 (hr) |
TW (3) | TWI807411B (hr) |
UY (1) | UY37706A (hr) |
WO (1) | WO2018197663A1 (hr) |
ZA (1) | ZA201907119B (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
MX2022013298A (es) | 2020-04-21 | 2022-11-30 | Pharma Mar Sa | Conjugados de anticuerpos de farmacos. |
TW202144369A (zh) * | 2020-04-26 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 海鞘素類衍生物及其製備方法與醫藥用途 |
IL308389A (en) | 2021-05-19 | 2024-01-01 | Pharma Mar Sa | Dosing regimens for acubactadine |
WO2024186263A1 (en) * | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
Family Cites Families (220)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3205220A (en) | 1961-10-26 | 1965-09-07 | Lilly Co Eli | Leurosidine and leurocristine and their production |
US4762949A (en) | 1979-06-20 | 1988-08-09 | University Of Illinois Foundation | Acyl and carbamimidoyl alkanediamines |
GB2058047B (en) | 1979-07-11 | 1983-09-21 | Asahi Chemical Ind | Amides and amidines |
FR2461995A1 (fr) | 1979-07-20 | 1981-02-06 | Lcc Cice Cie Europ Compo Elect | Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur |
US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
US4782135A (en) | 1980-09-12 | 1988-11-01 | Board Of Trustees, University Of Illinois | Composition of matter and process |
US5137870A (en) | 1980-09-12 | 1992-08-11 | The Board Of Trustees Of The University Of Illinois | Didemnins and nordidemnins |
DE3161556D1 (en) | 1980-09-12 | 1984-01-05 | Univ Illinois | Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them |
US4950649A (en) | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
US4548814A (en) | 1980-12-18 | 1985-10-22 | The Board Of Trustees Of The University Of Illinois | Composition of matter and process |
JPS5922518A (ja) | 1982-07-29 | 1984-02-04 | 余合住金産業株式会社 | 洋服タンス |
IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
US4855086A (en) | 1982-10-15 | 1989-08-08 | Burroughs Wellcome Co. | Novel pesticides, preparation and use |
US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
US4567253A (en) | 1984-02-03 | 1986-01-28 | Tony Durst | 2-Substituted derivatives of podophyllotoxin and etoposide |
JPS61109717A (ja) | 1984-11-02 | 1986-05-28 | Teruhiko Beppu | 抗腫瘍剤 |
AU585936B2 (en) | 1984-12-28 | 1989-06-29 | Conpharm A.B. | Pharmaceutically active podophyllotoxins |
US4644072A (en) | 1985-04-12 | 1987-02-17 | Bristol-Myers Company | Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof |
EP0220453B1 (de) | 1985-09-20 | 1992-04-15 | Cernitin S.A. | Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung |
US4731377A (en) | 1986-01-31 | 1988-03-15 | Harbor Branch Oceanographic Institute, Inc. | Antitumor cyclic peroxides |
AU589282B2 (en) | 1986-06-09 | 1989-10-05 | University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4737510A (en) | 1986-09-30 | 1988-04-12 | The Board Of Trustees Of The University Of Illinois | Bioactive metabolites from the caribbean sponge agelas coniferin |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US4847246A (en) | 1987-09-11 | 1989-07-11 | Wilson George R | Antiviral compositions derived from fireflies and their methods of use |
FR2623504B1 (fr) | 1987-11-25 | 1990-03-09 | Adir | Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
US5559145A (en) | 1988-06-01 | 1996-09-24 | Oxaco S.A. | 1,2,4-trioxane derivatives |
ES2054011T3 (es) | 1988-09-05 | 1994-08-01 | Sankyo Co | Un proceso para la preparacion de un compuesto, "leualacina". |
WO1990005731A1 (en) | 1988-11-24 | 1990-05-31 | University Of Queensland | Cytotoxic macromolecules |
US5190876A (en) | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
CA2007507C (en) | 1989-02-03 | 1998-05-19 | Yasuyuki Igarashi | Sphingosine and n-methyl-sphingosine as inhibitor of cell growth |
US5583160A (en) | 1989-02-03 | 1996-12-10 | The Biomembrane Institute | Methylsphingosine used to treat apoptosis |
US4948791A (en) | 1989-04-10 | 1990-08-14 | The Board Of Trustees Of The University Of Illinois | Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
US20030148933A1 (en) | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
US5053559A (en) | 1989-12-29 | 1991-10-01 | Oxaco S.A. | Cleavage of 1,2,4-trioxanes |
KR910014122A (ko) | 1990-01-19 | 1991-08-31 | 디께다 가즈히꼬 | 에토포시드-2-디메틸아미노 화합물의 동결건조 제제 |
JPH0539283A (ja) | 1991-01-31 | 1993-02-19 | Suntory Ltd | 新規物質S−59917a及びその製造方法 |
US5721352A (en) | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
DE4120327A1 (de) | 1991-06-20 | 1992-12-24 | Basf Ag | Neue peptide, ihre herstellung und verwendung |
US5336669A (en) | 1991-12-10 | 1994-08-09 | Erbamont, Inc. | Cyclophosphamide monohydrate and lactose |
JPH05247055A (ja) | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
GB9206244D0 (en) | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
GB9212000D0 (en) | 1992-06-05 | 1992-07-15 | Univ Madrid Complutense | New synthetic antitumoral compound |
AU4787693A (en) | 1992-08-12 | 1994-03-15 | Upjohn Company, The | Protein kinase inhibitors and related compounds combined with taxol |
US5756734A (en) | 1992-09-11 | 1998-05-26 | Pharmamar, S.A. | Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe |
ES2059259B1 (es) | 1992-09-22 | 1995-10-01 | Pharma Mar S A Pharmar | Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral. |
US5580871A (en) | 1992-11-20 | 1996-12-03 | The Dupont Merck Pharmaceutical Company | 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity |
US6274551B1 (en) | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
GB9302044D0 (en) | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Cytotoxic compounds i |
GB9302046D0 (en) | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
US5569757A (en) | 1993-03-30 | 1996-10-29 | Rinehart; Kenneth L. | 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1 |
GB9308111D0 (en) | 1993-04-20 | 1993-06-02 | Pharma Gen S A | Active compound from a stonge |
US5556777A (en) | 1993-09-09 | 1996-09-17 | Pharmamar, S.A. | Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp. |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
US5514708A (en) | 1994-02-18 | 1996-05-07 | Pharmamar, S.A. | Cytotoxic metabolites from Myriapora truncata |
US5681813A (en) | 1994-04-06 | 1997-10-28 | Pharma Mar, S.A. | Thiodepsipeptide isolated from a marine actinomycete |
ES2100124B1 (es) | 1994-08-01 | 1998-04-01 | Pharma Mar Sa | Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral. |
US5514705A (en) | 1994-09-07 | 1996-05-07 | Pharmamar, S.A. | Epidioxymanadic acids A and B |
US5523456A (en) | 1994-09-29 | 1996-06-04 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9422947D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Immunosuppressive cyclolignan derivatives |
GB9422946D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Antineoplastic cyclolignan derivatives |
GB9504662D0 (en) | 1995-03-08 | 1995-04-26 | Pharma Mar Sa | Antitumour isocoumarins |
US20010039041A1 (en) | 1995-06-07 | 2001-11-08 | Pharma Mar, S.A. | Immunosuppressive sesbanimide compositions and methods of treatment using same |
US5661175A (en) | 1995-06-20 | 1997-08-26 | Kashman; Yoel | Hemiasterlin and geodiamolide TA |
US5852033A (en) | 1995-06-29 | 1998-12-22 | Pharma Mar, S.A. | Methods of treatment using lamellarin-class alkaloids |
ES2102322B1 (es) | 1995-07-13 | 1998-03-01 | Pharma Mar Sa | Procedimiento de preparacion de didemnina a. |
US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
EP0821068A3 (en) | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
GB9608010D0 (en) | 1996-04-18 | 1996-06-19 | Pharma Mar Sa | Trunkamide A |
US6156724A (en) | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
AU726146B2 (en) | 1996-10-24 | 2000-11-02 | Board Of Trustees Of The University Of Illinois, The | Total synthesis of the amino hip analogue of didemnin A |
ATE321773T1 (de) | 1996-10-24 | 2006-04-15 | Univ Illinois | Semisynthetisches verfahren zur herstellung von didemninanalogen |
GB9622427D0 (en) | 1996-10-28 | 1997-01-08 | Pharma Mar Sa | Antimalarial drugs |
US6107520A (en) | 1997-04-15 | 2000-08-22 | The Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
US6800661B1 (en) | 1997-04-15 | 2004-10-05 | Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
US6034058A (en) | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
US6028077A (en) | 1997-04-15 | 2000-02-22 | Rinehart; Kenneth L. | Crambescidin compounds |
USRE38793E1 (en) | 1997-04-15 | 2005-09-06 | Rinehart Kenneth L | Spisulosine compounds |
US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
AUPO656597A0 (en) | 1997-05-02 | 1997-05-29 | Australian National University, The | Preparation of therapeutic compounds |
US6030943A (en) | 1997-05-07 | 2000-02-29 | Crumb; William J. | Dehydrodidemnin B as an L-type calcium channel enhancer |
GB9723206D0 (en) | 1997-11-03 | 1998-01-07 | Inst Biomar Sa | New cytotoxic pyridoacridine alkaloids |
US6420357B1 (en) | 1997-12-23 | 2002-07-16 | Instituto Biomar, S.A. | Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge |
GB9727301D0 (en) | 1997-12-23 | 1998-02-25 | Inst Biomar Sa | Asmarine A and B: New cytotoxic alkaloids |
GB9801741D0 (en) | 1998-01-27 | 1998-03-25 | Inst Biomar Sa | New cytotoxic tris (oxazole)-containing macrolides |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
DE69936845T2 (de) | 1998-04-06 | 2008-05-08 | The Board Of Trustees Of The University Of Illinois, Urbana | Halbsynthetische ectein-ascidine |
US6656948B2 (en) | 1998-04-29 | 2003-12-02 | Universidad Complutense De Madrid | Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system |
AU759494B2 (en) | 1998-05-05 | 2003-04-17 | Pharma Mar S.A. | Culture of sessile marine animals |
EP1077698B1 (en) | 1998-05-11 | 2005-03-02 | Pharma Mar, S.A. | Metabolites of ecteinascidin 743 |
GB9810998D0 (en) | 1998-05-21 | 1998-07-22 | Univ Madrid Complutense | Antitumour 1,5-diazaanthraquinones |
US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
GB9821975D0 (en) | 1998-10-08 | 1998-12-02 | Pharma Mar Sa | New cytotoxic alkaloids |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
GB9918178D0 (en) | 2000-05-15 | 1999-10-06 | Pharma Mar Sa | Synthetic methods |
AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
GB9915069D0 (en) | 1999-06-28 | 1999-08-25 | Inst Biomar Sa | New indolocarbazole alkaloids from a marine actinomycete |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
MXPA02004862A (es) | 1999-11-15 | 2003-01-28 | Pharma Mar Sa | Tratamiento de aplidina para canceres. |
AU783562B2 (en) | 2000-01-19 | 2005-11-10 | Trustees Of Columbia University In The City Of New York, The | Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
AU3387301A (en) | 2000-02-16 | 2001-08-27 | Pharma Mar Sa | Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity |
US20030187075A1 (en) | 2000-03-20 | 2003-10-02 | Junichi Tanaka Keith | Sponge antitumor compounds |
CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
US6509315B1 (en) | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
US7919493B2 (en) | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
PT1280809E (pt) * | 2000-04-12 | 2005-11-30 | Pharma Mar Sa | Derivados antitumorais de ecteinascidina |
GB0010799D0 (en) | 2000-05-04 | 2000-06-28 | Inst Biomar Sa | Stolonoxides |
US7420051B2 (en) | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
GB0011927D0 (en) | 2000-05-17 | 2000-07-05 | Inst Biomar Sa | New use of citreamicins |
IL153096A0 (en) | 2000-06-06 | 2003-06-24 | Pharma Mar Sa | Spisulosine analogs and pharmaceutical compositions containing the same |
GB0016020D0 (en) | 2000-06-29 | 2000-08-23 | Inst Biomar Sa | New polyciclic xanthones and their use |
UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
IL153682A0 (en) | 2000-07-11 | 2003-07-06 | Pharma Mar Sa | Variolin derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
AU7347101A (en) | 2000-07-13 | 2002-01-30 | Transurgical Inc | Thermal treatment methods and apparatus with focused energy application |
GB0019117D0 (en) | 2000-08-03 | 2000-09-27 | Univ Barcelona | Derivatives of variolin B |
EP1330254B1 (en) | 2000-10-12 | 2005-07-06 | Pharma Mar, S.A. | Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine |
CN1479622A (zh) | 2000-10-12 | 2004-03-03 | 联合使用阿普里汀和肌肉保护剂来治疗癌症 | |
WO2002036145A2 (en) | 2000-10-31 | 2002-05-10 | Pharma Mar, S.A. | Kahalalide f formulation |
DK1365808T3 (da) | 2000-11-06 | 2011-05-16 | Pharma Mar Sa | Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743 |
GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
EP1353659A1 (de) | 2001-01-24 | 2003-10-22 | Mestex AG | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen |
JP2004521122A (ja) | 2001-01-25 | 2004-07-15 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン類似体の非経口製剤 |
EP1360337A1 (en) | 2001-02-09 | 2003-11-12 | The Regents Of The University Of California | Ecteinascidin family compounds: compositions and methods |
GB0105745D0 (en) | 2001-03-08 | 2001-04-25 | Pharma Gen S A | Immobilisation of ligands |
GB0108234D0 (en) | 2001-04-02 | 2001-05-23 | Pharma Mar Sa | Process for producing trunkamide A compounds |
GB0116966D0 (en) | 2001-07-11 | 2001-09-05 | Pharma Mar Sa | Anittumoral compounds |
GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
US20050054555A1 (en) | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
WO2003033013A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Use of aplidine for the treatment of pancreatic cancer |
CA2462639A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Kahalalide compounds for use in cancer therapy |
RU2306933C2 (ru) | 2001-10-19 | 2007-09-27 | Фарма Мар, С.А. | Улучшенная схема применения противоопухолевого соединения в терапии рака |
GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
US20040019027A1 (en) | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
GB0217638D0 (en) | 2002-07-30 | 2002-09-11 | Pharma Mar Sa | Total synthesis of myriaporones |
HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
GB0218813D0 (en) | 2002-08-13 | 2002-09-18 | Pharma Mar Sa | DNA sequences from an endosymbiont and their uses |
GB0218816D0 (en) | 2002-08-13 | 2002-09-18 | Pharma Mar Sa | Antitumoral analogs of lamellarins |
US20040033940A1 (en) | 2002-08-16 | 2004-02-19 | Pharma Mar, S.A. | Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP |
EP1572726B1 (en) | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
GB0304367D0 (en) | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
GB0229793D0 (en) | 2002-12-20 | 2003-01-29 | Pharma Mar Sa | The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
GB0303940D0 (en) | 2003-02-20 | 2003-03-26 | Pharma Mar Sau | Solid phase synthesis of antitumoral compounds |
AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
RU2341283C2 (ru) | 2003-03-12 | 2008-12-20 | Фарма Мар, С.А. | Усовершенствованное лечение опухолей |
DK1603584T3 (da) | 2003-03-12 | 2009-01-05 | Dana Farber Cancer Inst Inc | Aplidine til behandling af multipelt myelom |
WO2004084812A2 (en) | 2003-03-21 | 2004-10-07 | Joullie Madeleine M | Tamandarin analogs and fragments thereof and methods of making and using |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
GB0312407D0 (en) | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
GB0314726D0 (en) | 2003-06-24 | 2003-07-30 | Inst Biomar Sa | New cytotoxic depsipeptides |
US7378410B2 (en) | 2003-07-25 | 2008-05-27 | Novartis Ag | Substituted lactams and their use as anti-cancer agents |
GB0321066D0 (en) | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
ATE419242T1 (de) | 2003-10-09 | 2009-01-15 | Abbott Lab | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
GB0324201D0 (en) | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
ATE406897T1 (de) | 2003-11-13 | 2008-09-15 | Pharma Mar Sau | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs |
GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
EP1691809A1 (en) * | 2003-11-14 | 2006-08-23 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
DE102004011809A1 (de) | 2004-03-11 | 2005-09-29 | Robert Bosch Gmbh | Magnetsensoranordnung |
GB0408958D0 (en) | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
WO2005118584A2 (en) | 2004-05-26 | 2005-12-15 | Axys Pharmaceuticals, Inc. | Saframycin analogs as therapeutic agents in the treatment of cancer |
US7446196B2 (en) | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
EP1768671A2 (en) | 2004-07-09 | 2007-04-04 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
WO2006035244A2 (en) | 2004-09-29 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
ATE430586T1 (de) | 2004-10-26 | 2009-05-15 | Pharma Mar Sa | Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743 |
DK1658848T3 (da) | 2004-10-29 | 2007-11-26 | Pharma Mar Sa | Formuleringer omfattende ecteinascidin og et disaccharid |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
WO2006066183A2 (en) | 2004-12-16 | 2006-06-22 | Axys Pharmaceuticals, Inc. | Novel saframycin analogs as therapeutic agents |
AU2006243407A1 (en) | 2005-05-03 | 2006-11-09 | Pharma Mar, S.A. | Antitumoral tetrahydro-pyrimidines |
GB0515673D0 (en) | 2005-08-01 | 2005-09-07 | Pharma Mar Sa | Antitumoral compounds |
EP1925668A2 (en) | 2005-08-02 | 2008-05-28 | Pharma Mar, S.A. | Genes involved in the biosynthesis of thiocoraline and heterologous production of same |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
GB0523098D0 (en) | 2005-11-14 | 2005-12-21 | Pharma Mar Sa | Antitumoral compounds |
JP2009517403A (ja) | 2005-11-25 | 2009-04-30 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー | Parp−1阻害剤の使用 |
ES2276629B1 (es) | 2005-12-15 | 2009-04-01 | Pharma Mar, S.A. | Compuestos antitumorales. |
ES2288107B1 (es) | 2006-01-27 | 2008-11-01 | Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita | Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa. |
PL2029155T3 (pl) | 2006-02-28 | 2016-09-30 | Ulepszony sposób leczenia szpiczaka mnogiego | |
US20100009906A1 (en) | 2006-05-12 | 2010-01-14 | Pharma Mar, S.A. | Anticancer Treatments |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
WO2007144423A1 (en) | 2006-06-16 | 2007-12-21 | Pharma Mar, S.A. | Antitumoral dihydropyran-2-one compounds |
CA2703024A1 (en) | 2007-10-19 | 2009-04-23 | Giuseppe Longo Sorbello | Improved antitumoral treatments |
JP2011500046A (ja) | 2007-10-19 | 2011-01-06 | ファルマ・マール・ソシエダード・アノニマ | Et−743治療のための予後分子マーカー |
EP2207561A2 (en) | 2007-10-19 | 2010-07-21 | Pharma Mar, S.A. | Improved antitumoral treatments |
CA2708080C (en) | 2007-12-14 | 2016-06-14 | Pharma Mar, S.A. | Antitumoral compounds |
RS53140B (en) | 2007-12-20 | 2014-06-30 | Pharma Mar S.A. | ANTITUMOR UNITS |
EP2252315A1 (en) | 2008-01-30 | 2010-11-24 | Pharma Mar, S.A. | Improved antitumoral treatments |
WO2009109649A1 (en) | 2008-03-07 | 2009-09-11 | Pharma Mar, S.A. | Improved antitumoral treatments |
KR20100131474A (ko) | 2008-03-07 | 2010-12-15 | 파르마 마르 에스.에이. | 개선된 항암치료 |
NZ589270A (en) | 2008-05-16 | 2011-12-22 | Pharma Mar Sa | Multiple myeloma treatments |
JP2011520921A (ja) | 2008-05-16 | 2011-07-21 | ファルマ・マール・ソシエダード・アノニマ | 抗腫瘍アルカロイドとの併用療法 |
MY155653A (en) | 2008-05-23 | 2015-11-13 | Wyeth Llc | Triazine compounds as p13 kinase and mtor inhibitors |
CA2729620A1 (en) | 2008-07-03 | 2010-01-07 | Pharma Mar, S.A. | Antitumoral macrolides |
RU2523419C2 (ru) | 2008-07-15 | 2014-07-20 | Дженетек, Инк. | Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений |
EP2318428A1 (en) | 2008-07-17 | 2011-05-11 | Pharma Mar S.A. | Anticancer compounds |
KR20110096169A (ko) | 2008-12-19 | 2011-08-29 | 파르마 마르 에스.에이. | 항암 화합물 |
WO2010149688A2 (en) | 2009-06-24 | 2010-12-29 | Pharma Mar, S.A. | Antitumoral compounds |
CN102947322B (zh) | 2010-04-27 | 2016-09-07 | 法马马有限公司 | 在7(8)位不饱和的抗癌甾体内酯 |
ES2534331T3 (es) | 2010-05-25 | 2015-04-21 | Pharma Mar S.A. | Proceso sintético para la producción de compuestos e intermedios de ecteinascidina |
RS58609B1 (sr) | 2010-11-12 | 2019-05-31 | Pharma Mar Sa | Kombinovana terapija sa inhibitorom mitoze |
DE102012211024A1 (de) | 2012-06-27 | 2014-01-02 | Robert Bosch Gmbh | Verfahren zum Betreiben eines Fahrzeuges |
JP5922518B2 (ja) | 2012-07-20 | 2016-05-24 | 浜松ホトニクス株式会社 | シンチレータパネル及び放射線検出器 |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
JOP20190254A1 (ar) * | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
-
2017
- 2017-06-16 JO JOP/2019/0254A patent/JOP20190254A1/ar unknown
-
2018
- 2018-04-27 FI FIEP22187664.2T patent/FI4101855T3/fi active
- 2018-04-27 DK DK18720255.1T patent/DK3615544T3/da active
- 2018-04-27 PT PT18382288T patent/PT3395821T/pt unknown
- 2018-04-27 UY UY0001037706A patent/UY37706A/es unknown
- 2018-04-27 DK DK22187664.2T patent/DK4101855T3/da active
- 2018-04-27 DK DK18382287.3T patent/DK3395820T3/da active
- 2018-04-27 FI FIEP18720255.1T patent/FI3615544T3/fi active
- 2018-04-27 MD MDE20221377T patent/MD4101855T2/ro unknown
- 2018-04-27 PL PL22187664.2T patent/PL4101855T3/pl unknown
- 2018-04-27 PL PL18720255.1T patent/PL3615544T3/pl unknown
- 2018-04-27 DK DK18382288.1T patent/DK3395821T3/da active
- 2018-04-27 CN CN202210424240.9A patent/CN114736219B/zh active Active
- 2018-04-27 HR HRP20231233TT patent/HRP20231233T1/hr unknown
- 2018-04-27 ES ES22187664T patent/ES2960063T3/es active Active
- 2018-04-27 PL PL22166571.4T patent/PL4047002T3/pl unknown
- 2018-04-27 DK DK22166571.4T patent/DK4047002T3/da active
- 2018-04-27 FI FIEP22166571.4T patent/FI4047002T3/fi active
- 2018-04-27 KR KR1020217032517A patent/KR102491180B1/ko active IP Right Grant
- 2018-04-27 MA MA44020A patent/MA44020B1/fr unknown
- 2018-04-27 LT LTEP22166571.4T patent/LT4047002T/lt unknown
- 2018-04-27 RS RS20230364A patent/RS64200B1/sr unknown
- 2018-04-27 JP JP2018086737A patent/JP6501947B2/ja active Active
- 2018-04-27 ES ES18382288T patent/ES2741901T3/es active Active
- 2018-04-27 SI SI201830966T patent/SI4101855T1/sl unknown
- 2018-04-27 MX MX2021016054A patent/MX2021016054A/es unknown
- 2018-04-27 TW TW110133271A patent/TWI807411B/zh active
- 2018-04-27 TW TW112129621A patent/TW202344509A/zh unknown
- 2018-04-27 RS RSP20191061 patent/RS59173B1/sr unknown
- 2018-04-27 US US15/964,381 patent/US10538535B2/en active Active
- 2018-04-27 HU HUE18382288A patent/HUE046109T2/hu unknown
- 2018-04-27 MD MDE20220945T patent/MD4047002T2/ro unknown
- 2018-04-27 ES ES18720255T patent/ES2944579T3/es active Active
- 2018-04-27 ME MEP-2019-228A patent/ME03466B/me unknown
- 2018-04-27 IL IL295044A patent/IL295044B2/en unknown
- 2018-04-27 SI SI201830902T patent/SI3615544T1/sl unknown
- 2018-04-27 WO PCT/EP2018/060868 patent/WO2018197663A1/en active Application Filing
- 2018-04-27 SG SG10201913300YA patent/SG10201913300YA/en unknown
- 2018-04-27 LT LTEPPCT/EP2018/060868T patent/LT3615544T/lt unknown
- 2018-04-27 EP EP18382288.1A patent/EP3395821B1/en active Active
- 2018-04-27 SI SI201830003T patent/SI3395821T1/sl unknown
- 2018-04-27 TW TW107114533A patent/TWI742273B/zh active
- 2018-04-27 LT LTEP22187664.2T patent/LT4101855T/lt unknown
- 2018-04-27 CN CN202210424238.1A patent/CN114751920B/zh active Active
- 2018-04-27 MX MX2019012812A patent/MX2019012812A/es unknown
- 2018-04-27 ES ES18382287T patent/ES2740073T3/es active Active
- 2018-04-27 RS RSP20191062 patent/RS59174B1/sr unknown
- 2018-04-27 PL PL18382288T patent/PL3395821T3/pl unknown
- 2018-04-27 RS RS20230905A patent/RS64686B1/sr unknown
- 2018-04-27 PT PT18382287T patent/PT3395820T/pt unknown
- 2018-04-27 SI SI201830002T patent/SI3395820T1/sl unknown
- 2018-04-27 ES ES22166571T patent/ES2944344T3/es active Active
- 2018-04-27 MD MDE20181216 patent/MD3395820T2/ro unknown
- 2018-04-27 TN TNP/2019/000210A patent/TN2019000210A1/en unknown
- 2018-04-27 CN CN201880027781.XA patent/CN110621678B/zh active Active
- 2018-04-27 MD MDE20200225T patent/MD3615544T2/ro unknown
- 2018-04-27 US US16/608,617 patent/US11332480B2/en active Active
- 2018-04-27 PL PL18382287T patent/PL3395820T3/pl unknown
- 2018-04-27 HU HUE18382287A patent/HUE045641T2/hu unknown
- 2018-04-27 HU HUE22187664A patent/HUE063736T2/hu unknown
- 2018-04-27 MA MA44021A patent/MA44021B1/fr unknown
- 2018-04-27 CA CA3061518A patent/CA3061518A1/en active Pending
- 2018-04-27 SG SG11201909841R patent/SG11201909841RA/en unknown
- 2018-04-27 JP JP2019558467A patent/JP7186723B2/ja active Active
- 2018-04-27 HR HRP20230455TT patent/HRP20230455T1/hr unknown
- 2018-04-27 ME MEP-2019-227A patent/ME03467B/me unknown
- 2018-04-27 HR HRP20230433TT patent/HRP20230433T1/hr unknown
- 2018-04-27 IL IL270153A patent/IL270153B2/en unknown
- 2018-04-27 HU HUE18720255A patent/HUE062157T2/hu unknown
- 2018-04-27 CN CN202410023357.5A patent/CN117865987A/zh active Pending
- 2018-04-27 IL IL289963A patent/IL289963B2/en unknown
- 2018-04-27 EP EP22166571.4A patent/EP4047002B1/en active Active
- 2018-04-27 EP EP18382287.3A patent/EP3395820B1/en active Active
- 2018-04-27 RS RS20230332A patent/RS64174B1/sr unknown
- 2018-04-27 SI SI201830901T patent/SI4047002T1/sl unknown
- 2018-04-27 KR KR1020227026211A patent/KR102510975B1/ko active IP Right Grant
- 2018-04-27 MD MDE20181217 patent/MD3395821T2/ro unknown
- 2018-04-27 EP EP22187664.2A patent/EP4101855B9/en active Active
- 2018-04-27 LT LTEP18382288.1T patent/LT3395821T/lt unknown
- 2018-04-27 KR KR1020197032625A patent/KR102492283B1/ko active IP Right Grant
- 2018-04-27 MY MYPI2019006255A patent/MY198004A/en unknown
- 2018-04-27 BR BR112019022282A patent/BR112019022282A2/pt unknown
- 2018-04-27 AU AU2018260314A patent/AU2018260314C1/en active Active
- 2018-04-27 TN TNP/2019/000211A patent/TN2019000211A1/en unknown
- 2018-04-27 LT LTEP18382287.3T patent/LT3395820T/lt unknown
- 2018-04-27 JP JP2018086736A patent/JP6501946B2/ja active Active
- 2018-04-27 EP EP18720255.1A patent/EP3615544B9/en active Active
- 2018-04-27 HU HUE22166571A patent/HUE062032T2/hu unknown
- 2018-11-23 HK HK18115007.9A patent/HK1255938B/zh unknown
- 2018-11-23 HK HK18115010.4A patent/HK1255941B/zh unknown
-
2019
- 2019-08-09 HR HRP20191443 patent/HRP20191443T1/hr unknown
- 2019-08-09 HR HRP20191442 patent/HRP20191442T1/hr unknown
- 2019-08-13 CY CY20191100872T patent/CY1121884T1/el unknown
- 2019-08-13 CY CY20191100873T patent/CY1121885T1/el unknown
- 2019-10-24 CL CL2019003057A patent/CL2019003057A1/es unknown
- 2019-10-25 MX MX2021016058A patent/MX2021016058A/es unknown
- 2019-10-25 CO CONC2019/0011967A patent/CO2019011967A2/es unknown
- 2019-10-25 PH PH12019550224A patent/PH12019550224A1/en unknown
- 2019-10-28 ZA ZA2019/07119A patent/ZA201907119B/en unknown
- 2019-11-26 EC ECSENADI201983967A patent/ECSP19083967A/es unknown
-
2021
- 2021-04-02 US US17/221,445 patent/US11339180B2/en active Active
-
2022
- 2022-01-14 AU AU2022200250A patent/AU2022200250C1/en active Active
- 2022-01-14 AU AU2022200249A patent/AU2022200249C1/en active Active
- 2022-03-09 AU AU2022201657A patent/AU2022201657A1/en not_active Abandoned
- 2022-04-05 US US17/714,114 patent/US11713325B2/en active Active
- 2022-07-04 JP JP2022107785A patent/JP7422812B2/ja active Active
-
2023
- 2023-01-24 JP JP2023008821A patent/JP7490835B2/ja active Active
- 2023-06-15 CY CY20231100283T patent/CY1126061T1/el unknown
- 2023-06-22 US US18/213,082 patent/US20240166666A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230433T1 (hr) | Antitumorski spojevi | |
AU2019201403B2 (en) | Aza-pyridone compounds and uses thereof | |
EP3532069A1 (en) | Antiviral aryl-amide phosphodiamide compounds | |
JP2024029066A (ja) | ガンの治療方法 | |
ES2924111T3 (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
KR101174672B1 (ko) | 항증식제로서의 피리도- 및 피리미도피리미딘 유도체 | |
CN106977584B (zh) | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 | |
AU2016229147C1 (en) | Aza-pyridone compounds and uses thereof | |
UA118760C2 (uk) | Заміщені нуклеозиди, нуклеотиди та їх аналоги | |
HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
JP2018188432A5 (hr) | ||
JP2018188431A5 (hr) | ||
CN102356085A (zh) | 具有脯氨酸环结构的咪唑并噻唑衍生物 | |
Jiang et al. | Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity | |
CN111072682A (zh) | 白屈菜碱呋咱类一氧化氮供体衍生物及其制备方法和用途 | |
EP2686337A1 (en) | Oligopeptides and process for preparation thereof | |
CA2253914C (en) | Camptothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents | |
EP2094653B1 (en) | O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists | |
US20070135436A1 (en) | Chemical compounds | |
CN109134511B (zh) | C19位氟代的Largazole类似物、其制备方法和用途 | |
HRP20201274T1 (hr) | Novi fosfotriazoli mrna s analognom cap-a na kraju 5', pripravci koji ih sadržavaju, rna molekule koje ih uključuju u svojem sastavu, njihova upotreba i postupak sinteze rna molekule, proteina ili peptida | |
CN104402818B (zh) | 一种具有肿瘤响应性释放药物的化合物或其药用盐及其制备、应用 | |
WO2023011359A1 (zh) | 桥环类化合物及其应用 | |
CN104327089A (zh) | 水溶性冬凌草甲素衍生物及其制备方法 | |
TH1901006825A (th) | สารประกอบต้านสิ่งที่เป็นเนื้องอก |